8-K: Coherus Oncology Recasts Financials Post-Biosimilar Divestitures

Coherus Oncology has retrospectively reclassified its biosimilar businesses as discontinued operations following major divestitures, shifting focus to innovative immuno-oncology.

Summary

• Coherus Oncology, Inc. has recast its financial statements for 2024 and 2023 to reflect its biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI franchises) as discontinued operations.
• This reclassification follows the strategic divestiture of these businesses, with the UDENYCA Sale to Intas Pharmaceuticals Ltd. completed on April 11, 2025, for $483.4 million upfront cash, plus potential earn-outs of two $37.5 million payments.
• The YUSIMRY immunology franchise was sold to HKF on June 26, 2024, for $40.0 million cash and assumption of $17.0 million in inventory commitments, resulting in a $22.8 million net gain.
• The CIMERLI ophthalmology franchise was sold to Sandoz on March 1, 2024, for $170.0 million cash plus $17.8 million for inventory, resulting in a $153.8 million net gain.
• The company reported a net income of $28.5 million in 2024, a significant improvement from a net loss of $237.9 million in 2023, primarily driven by the gains from these divestitures.
• Net income from discontinued operations, net of tax, was $243.9 million in 2024, compared to a net loss of $16.1 million in 2023.
• Continuing operations, focused on oncology, reported a net loss of $215.4 million in 2024 and $221.8 million in 2023.
• LOQTORZI, the company's approved PD-1 inhibitor, generated net revenue of $19.1 million in 2024, up from $0.6 million in 2023.
• The company used proceeds from the UDENYCA Sale to repay substantially all of its 2026 Convertible Notes and buy out UDENYCA royalty rights for $47.7 million in Q2 2025.

Sentiment

Score: 7

Explanation: The strategic shift to a focused immuno-oncology company, coupled with significant debt reduction and a positive net income in 2024 (driven by divestitures), is a strong positive. LOQTORZI's market acceptance and NCCN guideline inclusion are also favorable. However, the continuing operations still show a net loss, and the pipeline candidates require substantial R&D investment, indicating ongoing financial challenges and execution risk.

Positives

• Successful divestiture of all biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) for significant cash proceeds totaling $693.4 million upfront (UDENYCA $483.4M, CIMERLI $187.8M, YUSIMRY $40.0M).
• Potential for additional earn-out payments of up to $75.0 million from the UDENYCA Sale based on future net sales performance.
• Achieved a net income of $28.5 million in 2024, a substantial improvement from a $237.9 million net loss in 2023, largely due to gains on divestitures.
• Repaid substantially all of the $230.0 million aggregate principal amount of 2026 Convertible Notes and bought out UDENYCA royalty rights for $47.7 million in Q2 2025, significantly reducing debt and future obligations.
• LOQTORZI, the company's key oncology product, saw net revenue increase from $0.6 million in 2023 to $19.1 million in 2024, following its U.S. launch in January 2024.
• LOQTORZI is included as the only preferred Category 1 first-line treatment option in NCCN clinical practice guidelines for metastatic or recurrent locally advanced NPC.
• Maintained a cash and cash equivalents balance of $126.0 million as of December 31, 2024, and believes it has sufficient liquidity for at least the next 12 months.

Negatives

• Continuing operations reported a net loss of $215.4 million in 2024, indicating that the core oncology business is not yet profitable.
• Research and development expenses for continuing operations remain high at $91.8 million in 2024, reflecting ongoing investment in the immuno-oncology pipeline.
• Selling, general and administrative expenses for continuing operations increased to $125.5 million in 2024, partly due to a $6.8 million net impairment charge and increased professional services.
• Experienced a prolonged supply interruption for UDENYCA in Q4 2024 due to CMO over-commitments and capacity constraints, impacting sales before its divestiture.
• Incurred a $12.6 million loss on debt extinguishment in 2024 related to the payoff of the 2027 Term Loans.
• The exclusive license of NZV930 to Novartis Institutes was terminated, resulting in a $10.6 million impairment charge for the out-license intangible asset in Q1 2024.

Risks

• Ability to maintain or increase sales for LOQTORZI.
• Ability to develop and commercialize product candidates.
• Maintaining regulatory approval for LOQTORZI and obtaining approval for product candidates.
• Government and third-party payer coverage and reimbursement.
• Ability to manufacture products and product candidates in conformity with regulatory requirements and scale up capacity.
• Reliance on third-party contract manufacturers and contract research organizations.
• Potential market size and patient populations for products and product candidates.
• Ability to make required future interest and principal payments on debt obligations.
• Potential risks, disruptions, and losses from future cyberattacks and security incidents.
• Rate and degree of market acceptance of current or future products.
• Competition from companies producing competitor products.
• Effects of geopolitical conflicts (war in Ukraine, Middle East conflicts) on business and prospects.
• Uncertainty regarding the achievement of the $37.5 million earn-out payments from the UDENYCA divestiture, as they depend on post-closing net sales.
• Litigation costs, timing, and outcomes, including the $14.0 million claim from Zinc Health Services, LLC.
• Future funding requirements may necessitate raising additional funds, with no assurance of success or favorable terms.
• Changes in assumptions for inventory write-downs could lead to future charges if market conditions are less favorable than projected.

Future Outlook

The company expects net revenue from continuing operations in 2025 to be higher than 2024 due to continued growth of LOQTORZI. Research and development expenses are also expected to be higher in 2025 due to continued investments in the immuno-oncology pipeline. Conversely, selling, general and administrative expenses and interest expense from continuing operations are projected to be lower in 2025, primarily due to decreased operating costs, headcount reductions from divestitures, and debt repayments. The company believes its available cash, product sales, and transition service agreement income will be sufficient to fund planned expenditures and meet obligations for at least the next 12 months.

Management Comments

• "Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations."
• "We expect to further leverage these capabilities as we continue to advance our immuno-oncology franchise."
• "We believe that our available cash, cash equivalents, and cash collected from product sales and services provided under transition service agreements will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following the date of this Annual Report on Form 10-K."

Industry Context

This announcement signifies a complete strategic pivot for Coherus Oncology, Inc. from a diversified biosimilar and oncology company to an exclusive focus on innovative immuno-oncology medicines. This move aligns with a broader industry trend where pharmaceutical companies often streamline their portfolios to concentrate on high-growth, high-margin innovative drug development, particularly in specialized areas like oncology. By divesting its biosimilar assets, Coherus aims to reduce operational complexity and reallocate resources towards its proprietary pipeline, such as LOQTORZI, casdozokitug, and CHS-114, which target significant unmet needs in cancer treatment. This specialization could enhance its competitive position against larger, more diversified pharmaceutical companies by allowing for a more concentrated R&D and commercialization effort in a high-value therapeutic area.

Comparison to Industry Standards

• The strategic shift to an exclusive immuno-oncology focus is comparable to moves by other biopharmaceutical companies seeking to specialize in high-growth, innovative segments, such as Bristol Myers Squibb's focus on oncology and immunology or Merck's emphasis on its Keytruda franchise.
• The divestiture of biosimilar assets, while generating significant cash, contrasts with companies like Amgen or Pfizer, which maintain robust biosimilar portfolios as a revenue stream. Coherus's decision suggests a belief that higher long-term value lies in proprietary innovation rather than biosimilar competition.
• LOQTORZI's inclusion as the only preferred Category 1 first-line treatment option in NCCN guidelines for NPC positions it favorably against competitors in this specific indication, reflecting strong clinical evidence and market acceptance.
• The company's R&D spending of $91.8 million in 2024 for continuing operations, while substantial, is typical for a clinical-stage oncology company advancing multiple candidates (casdozokitug, CHS-114) and expanding indications for an approved product (LOQTORZI). This level of investment is necessary to compete with larger players like Roche or AstraZeneca in the immuno-oncology space.

Management Changes

Corporate Governance

Legal Proceedings

• Demand letter from Zinc Health Services, LLC asserting a claim of approximately $14.0 million for UDENYCA sales from October 2020 through December 2021.
• An accrual of $6.4 million was established as of December 31, 2024, representing the estimated liability to resolve this matter.
• The company intends to defend any legal proceeding that may be filed, and any liability is not expected to transfer to Intas as part of the UDENYCA Sale.

Stakeholder Impact

• Shareholders: Significant strategic shift towards a focused oncology company, potential for long-term value creation from innovative pipeline, but also short-term dilution risk from ATM offering and ongoing losses from continuing operations.
• Employees: Reduction in force in Q1 2023 impacted approximately 50 employees; lower headcount expected in 2025 due to divestitures, indicating workforce restructuring.
• Customers: UDENYCA customers experienced a prolonged supply interruption in Q4 2024, which was later resolved with supply allocations removed by end of February 2025.
• Creditors: Substantial repayment of 2026 Convertible Notes and 2027 Term Loans significantly reduces the company's debt burden, improving credit profile.
• Partners (e.g., Junshi Biosciences, Apotex): Continued collaboration on LOQTORZI development and commercialization, with new licensing agreements (Canada License Agreement) expanding market reach. Termination of TIGIT Program with Junshi Biosciences indicates portfolio optimization.

Next Steps

• Grow sales of LOQTORZI in nasopharyngeal carcinoma (NPC).
• Advance the development of new indications for LOQTORZI in combination with pipeline candidates and partners.
• Further evaluate LOQTORZI through multiple current and planned clinical studies by the company and its partners.
• Continue enrolling patients in a postmarketing commitment study for toripalimab in advanced NPC (NCT06457503).
• Junshi Biosciences is enrolling in a multiregional Phase 3 clinical study evaluating LOQTORZI with an investigational anti-BTLA antibody in LS-SCLC (NCT06095583).
• INOVIO Pharmaceuticals, Inc. plans a randomized Phase 3 study of INO-3112 and toripalimab in HPV16/18+ oropharyngeal squamous cell carcinoma.
• CRI plans to evaluate toripalimab in combination with ENB-003 in a Phase 2 trial for platinum-resistant high-grade serous ovarian cancer (NCT04918186).
• Initiate a Phase 1b clinical study of CHS-114 in combination with toripalimab in second-line HNSCC in Q1 2025 (NCT05635643).
• Initiate a Phase 1b clinical study of CHS-114 in combination with toripalimab and/or other treatments in advanced solid tumors (first cohort gastric cancer) in Q1 2025 (NCT06657144).
• Wind down work with Junshi Biosciences on the TIGIT Program following termination notice in January 2024.
• Monitor UDENYCA Net Sales for potential earn-out payments from Intas (first payment if Net Sales >= $300 million by Sep 30, 2026; second if Net Sales >= $350 million by Mar 31, 2027).
• Evaluate potential need to raise additional funds in the future.

Key Dates

Recommendation

The company has undergone a significant strategic transformation, divesting its biosimilar businesses to focus exclusively on immuno-oncology. This move, while generating substantial cash and enabling significant debt reduction, means the company is now a pure-play oncology firm with an approved product (LOQTORZI) and a pipeline. The 2024 net income was driven by one-time gains from divestitures, and continuing operations remain unprofitable. The future success hinges on LOQTORZI's growth and the successful development of pipeline candidates. Given the major strategic shift and the transition period, a "hold" recommendation is appropriate for investors to observe the execution of the new strategy and the financial performance of the focused oncology business. The potential for future growth is there, but so are the inherent risks of drug development and commercialization in a competitive market.

Keywords

Coherus Oncology, immuno-oncology, LOQTORZI, biosimilar divestiture, UDENYCA, YUSIMRY, CIMERLI, SEC filing, financial recast, oncology pipeline, biotechnology, pharmaceuticals, cancer treatment, PD-1 inhibitor, asset sale, debt repayment, financial results